Compare Stocks: VCYT, TWST, BMRN, and EXEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$66.70 -1.4%	$60.67	$49.26 ▼ $70.98	$12.91B	0.24	2.33 million shs	1.59 million shs
EXEL Exelixis	$54.08 +0.7%	$54.26	$33.76 ▼ $57.57	$13.40B	0.44	2.75 million shs	1.95 million shs
TWST Twist Bioscience	$145.59 +6.8%	$100.69	$23.30 ▼ $145.93	$9.13B	2.14	1.74 million shs	1.79 million shs
VCYT Veracyte	$42.31 +1.2%	$52.72	$28.25 ▼ $60.91	$3.40B	1.95	1.42 million shs	1.01 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	0.00%	-0.98%	+13.30%	+23.31%	+15.08%
EXEL Exelixis	0.00%	+5.54%	-2.82%	+7.84%	+42.84%
TWST Twist Bioscience	0.00%	+22.79%	+57.50%	+140.37%	+450.43%
VCYT Veracyte	0.00%	+2.57%	-26.90%	-6.04%	+43.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$66.70 -1.4%	$60.67	$49.26 ▼ $70.98	$12.91B	0.24	2.33 million shs	1.59 million shs
EXEL Exelixis	$54.08 +0.7%	$54.26	$33.76 ▼ $57.57	$13.40B	0.44	2.75 million shs	1.95 million shs
TWST Twist Bioscience	$145.59 +6.8%	$100.69	$23.30 ▼ $145.93	$9.13B	2.14	1.74 million shs	1.79 million shs
VCYT Veracyte	$42.31 +1.2%	$52.72	$28.25 ▼ $60.91	$3.40B	1.95	1.42 million shs	1.01 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	0.00%	-0.98%	+13.30%	+23.31%	+15.08%
EXEL Exelixis	0.00%	+5.54%	-2.82%	+7.84%	+42.84%
TWST Twist Bioscience	0.00%	+22.79%	+57.50%	+140.37%	+450.43%
VCYT Veracyte	0.00%	+2.57%	-26.90%	-6.04%	+43.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.83	33.17% Upside
EXEL Exelixis	2.30	Hold	$50.07	-7.42% Downside
TWST Twist Bioscience	2.70	Moderate Buy	$98.30	-32.48% Downside
VCYT Veracyte	2.82	Moderate Buy	$54.33	28.42% Upside

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and EXEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/10/2026	BMRN BioMarin Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$111.00 ➝ $114.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	4.01	$2.85 per share	23.38	$32.66 per share	2.04
EXEL Exelixis	$2.32B	5.78	$3.03 per share	17.86	$7.44 per share	7.27
TWST Twist Bioscience	$376.57M	24.25	N/A	N/A	$7.11 per share	20.48
VCYT Veracyte	$517.15M	6.58	$1.49 per share	28.41	$17.27 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	180.27	12.35	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.01	14.54	1.61	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	N/A
VCYT Veracyte	$66.35M	$1.41	30.01	27.47	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest VCYT, TWST, BMRN, and EXEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
TWST Twist Bioscience	0.03	2.67	2.38
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
TWST Twist Bioscience	N/A
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
TWST Twist Bioscience	3.08%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
TWST Twist Bioscience	990	62.71 million	60.78 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

VCYT, TWST, BMRN, and EXEL Headlines

Recent News About These Companies

BlackRock Inc. Acquires New Position in Veracyte, Inc. $VCYT

August 23 at 3:28 AM | marketbeat.com

1,431,596 Shares in Veracyte, Inc. $VCYT Bought by William Blair Investment Management LLC

August 22 at 6:47 AM | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by Brokerages

August 22 at 2:15 AM | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Brokerages

August 22 at 2:13 AM | marketbeat.com

Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT

August 21 at 6:31 AM | marketbeat.com

Great Lakes Advisors LLC Invests $3.85 Million in Veracyte, Inc. $VCYT

August 21 at 4:00 AM | marketbeat.com

Lisanti Capital Growth LLC Purchases Shares of 63,400 Veracyte, Inc. $VCYT

August 20 at 6:23 AM | marketbeat.com

Head-To-Head Review: CAMP4 Therapeutics (NASDAQ:CAMP) & Veracyte (NASDAQ:VCYT)

August 20 at 2:16 AM | americanbankingnews.com

Summit Creek Advisors LLC Takes Position in Veracyte, Inc. $VCYT

August 19, 2026 | marketbeat.com

Rice Hall James & Associates LLC Invests $5.61 Million in Veracyte, Inc. $VCYT

August 18, 2026 | marketbeat.com

Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround

August 17, 2026 | zacks.com

Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy

August 13, 2026 | marketbeat.com

Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT

August 13, 2026 | marketbeat.com

Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT

August 12, 2026 | marketbeat.com

Veracyte: Diagnostics With Favorable Economics

August 10, 2026 | seekingalpha.com

Veracyte: Core Growth Funds Prosigna And TrueMRD

August 9, 2026 | seekingalpha.com

Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT

August 7, 2026 | marketbeat.com

Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC

August 7, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Growth Story Gains Fresh Market Attention

August 6, 2026 | kalkinemedia.comK

Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT

August 6, 2026 | marketbeat.com

Renaissance Technologies LLC Takes Position in Veracyte, Inc. $VCYT

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, BMRN, and EXEL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$66.70 -0.98 (-1.45%)

As of 08/21/2026 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$54.08 +0.39 (+0.73%)

As of 08/21/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Twist Bioscience NASDAQ:TWST

$145.59 +9.26 (+6.79%)

As of 08/21/2026 04:00 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte NASDAQ:VCYT

$42.31 +0.52 (+1.24%)

As of 08/21/2026 04:00 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, BMRN, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, BMRN, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, BMRN, and EXEL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and EXEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, BMRN, and EXEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, BMRN, and EXEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, BMRN, and EXEL Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools